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Abstract
Background: Prone whole breast irradiation (WBI) leads to reduced heart and lung doses in breast cancer patients
receiving adjuvant radiotherapy. In this feasibility trial, we investigated the prone position for whole breast + lymph
node irradiation (WB + LNI).
Methods: A new support device was developed for optimal target coverage, on which patients are positioned in a
position resembling a phase from the crawl swimming technique (prone crawl position). Five left sided breast cancer
patients were included and simulated in supine and prone position. For each patient, a treatment plan was made in
prone and supine position for WB + LNI to the whole axilla and the unoperated part of the axilla. Patients served as their
own controls for comparing dosimetry of target volumes and organs at risk (OAR) in prone versus in supine position.
Results: Target volume coverage differed only slightly between prone and supine position. Doses were significantly
reduced (P < 0.05) in prone position for ipsilateral lung (Dmean, D2, V5, V10, V20, V30), contralateral lung (Dmean,
D2), contralateral breast (Dmean, D2 and for total axillary WB + LNI also V5), thyroid (Dmean, D2, V5, V10, V20, V30),
oesophagus (Dmean and for partial axillary WB + LNI also D2 and V5), skin (D2 and for partial axillary WB + LNI V105
and V107). There were no significant differences for heart and humeral head doses.
Conclusions: Prone crawl position in WB + LNI allows for good breast and nodal target coverage with better sparing
of ipsilateral lung, thyroid, contralateral breast, contralateral lung and oesophagus when compared to supine position.
There is no difference in heart and humeral head doses.
Trial registration: No trial registration was performed because there were no therapeutic interventions.
Keywords: Adjuvant radiotherapy, Breast irradiation, Regional nodal irradiation, Breast cancer, Prone position, Prone
crawl position, Dosimetry, Organs at risk, VMAT
Background
Locoregional irradiation in breast cancer decreases re-
currences and breast cancer mortality in patients with
positive lymph nodes [1–3]. Traditionally, locoregional
irradiation has been administered by using two high
tangential fields with the patient in supine position. These
techniques have demonstrated to insufficiently dose the
axillary lymph node regions [4, 5]. Separate boost fields
could be added to the axilla and the supraclavicular region
to improve coverage of these areas, at the cost of higher
OAR doses [6]. Newer techniques such as intensity modu-
lated radiotherapy (IMRT) and volumetric modulated arc
therapy (VMAT) [7–9] have led to dosimetrical benefits,
including better sparing of organs at risk (OARs) and bet-
ter dose homogeneity, but with higher volumes of healthy
tissue receiving low dose.
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Aside from these techniques, other ways to decrease
the dose to the heart and lungs have been implemented
in whole breast irradiation (WBI), such as the prone
position. A comparative dosimetrical study shows that in
prone position, even simple wedged tangential fields im-
prove dose to the ipsilateral lung when compared to any
of the more advanced static supine techniques used [8].
Other authors agree that the prone position allows for
better sparing of the ipsilateral lung [8, 10, 11]. In left
sided breast cancer, the dose to the heart is also de-
creased in the majority of patients by using the prone
position, but published results show this might not be
the case for all patients [8, 10–13]. Therefore, additional
efforts were made to lower the dose to the heart by
using breath-hold or gating techniques [14–17].
Although some authors report dosimetrical data on re-
gional nodal irradiation in prone position [18, 19], this
indication has not seen the same shift towards prone ir-
radiation as in WBI, and few data are available for clin-
ical implementation [20].
Commercially available devices for prone breast irradi-
ation typically support the patient with both arms elevated
alongside the head. One of the major disadvantages of
treating patients in this position, however, is that the sup-
port material itself obstructs the anterior beam access to
the regional lymph nodes, which creates a bolus effect
with possible associated skin toxicities. The use of other
beam directions increases the trajectory through healthy
tissues and therefore increases doses to OARs [18, 21].
The aim to obtain unobstructed beam access to the
breast and its regional lymph nodes while maintaining the
benefits of the prone position regarding dose to the organs
at risk (OAR) led to the investigation of a new patient
prone position and its specifically adapted patient support
surface. In this prone position, the arm of the patient at
the treated side is positioned alongside the body, the arm
at the contralateral side above the head. This study pre-
sents data on the feasibility of whole-breast irradiation
with lymph node irradiation (WB + LNI) in this position.
Methods
Prone crawl positioning device
To overcome the disadvantages of conventional prone
positioning aids, our team developed a prototype with a
surface not directly supporting the target regions for
WB + LNI such as the axillary, periclavicular or ipsilat-
eral internal mammary nodal regions or the treated
breast [Fig. 1]. The prototype does not rest entirely on
the treatment couch, as is usually the case in prone posi-
tioning devices, further called breast boards. The device
is anchored on the caudal part of the treatment couch,
while the cranial part of the couch is removed to allow
for an overhanging position of the prototype without
support from the treatment unit couch [Fig. 1]. This de-
sign – further called a breast couch – allows the use of a
floor laser for patient positioning, which can help to re-
duce lateral setup errors. The patient is positioned on
the breast couch with the ipsilateral arm next to the
body and the contralateral arm elevated alongside the
head. This improves comfort for the operated axilla.
Using the ipsilateral arm support as a waist support im-
proved stability, by preventing patients from sliding
down from the wedge. We refer to this position as the
crawl position, because it resembles a phase of the crawl
swimming technique.
Patient selection
Five left sided breast cancer patients with invasive carcin-
oma of the breast and pathologically confirmed positive
lymph node status were included in our study. All patients
underwent lumpectomy and axillary clearance followed by
adjuvant WB+ LNI in supine position. Informed consent
was obtained before simulation for each patient. The study
was approved by the local ethics board.
Simulation
Patients were positioned and scanned in both the supine
and prone crawl position. In supine position, patients
were positioned using a Posirest arm support (Civco
Fig. 1 Patient setup on a prototype of the crawl breast couch. a The ipsilateral arm is positioned on a support along the waist. The head is
turned away from the ispilateral side towards the contralateral arm, which is extended along the head. b Red floor laser beam projected on
the breast
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Medical Solutions, Kalone, Iowa, United States) with
both arms elevated above the head. Opaque wires were
positioned around the contours of both breasts, as well
as on the tumorectomy scar. Patients were administered
IV iodine contrast prior to scanning. After supine
simulation, patients were positioned on the crawl breast
couch for prone simulation. An opaque wire was only
placed around the ipsilateral breast and surgical
incision. The contralateral breast was pulled laterally,
away from the ipsilateral breast to increase distance to
the irradiated area and fixated in a unilateral bra [22].
For both positions, 5 mm slice thickness images were
acquired on a Siemens SOMATOM definition AS
computed tomography-scan (Siemens Healthineers,
Erlangen, Germany), starting at the vertex and caudally
including the whole breast and both lungs.
Target volume delineation
All contours were delineated on the Pinnacle3 9.8 treat-
ment planning system (Philips Healthcare, Fitchburg,
Wisconsin, United States). In supine position, clinical target
volumes for whole breast irradiation (CTV_WBI) and
lymph node irradiation (CTV_LNI) were defined according
to the contouring guidelines as proposed by the ESTRO
and PROCAB groups [23–26]. As there are no generally
accepted guidelines for delineation in prone position, we
performed delineation of CTV_WBI and CTV_LNI using
extrapolation from the guidelines described above.
For each patient, two sets of CTV_LNI were delin-
eated: the whole axilla (level I-II-III-IV) and the partial
axilla (level II-III-IV, i.e. the undissected axillary regions
after surgical clearance). Internal mammary nodes were
not contoured or included in any of the treatment vol-
umes. Planning target volume was obtained by perform-
ing an isometric expansion of CTV_WBI and CTV_LNI
by 5 mm and 3 mm, respectively, thereby creating
PTV_WBI and PTV_LNI. For PTV_WBI no expansion
in the medial direction was done to avoid irradiation of
the contralateral breast. Planning optimization struc-
tures (PTV_WBI_opt and PTV_LNI_opt) were created
to account for dose buildup underneath the skin. The
structures were made by retracting PTV_WBI and
PTV_LNI 8 mm away from the skin and excluding the
heart, lung and contralateral breast, all with an expan-
sion of 8 mm, adding the delineated clinical target vol-
umes. Because these optimization structures are the
structures used in planning, they will be referred to from
hereon as the PTV_WBI and PTV_LNI, unless specific-
ally stated otherwise. All delineations were performed by
the same experienced radiation oncologist.
Organs at risk (OAR) delineation
The heart was delineated in accordance with guidelines
proposed by Feng et al. [27]. Left and right lungs were
contoured separately using automatic segmentation by
Hounsfield units options provided in Pinnacle3 9.8 with
threshold 800–4096. The contralateral breast was delin-
eated up to the skin. The thyroid was manually delin-
eated where visible, as was the oesophagus, starting
cranially from the inferior margin of the cricoid and
ending inferiorly at the gastro-oesophageal margin. The
humeral head was delineated from the most proximal
part to the lower border of the tuberculum maius. The
skin was defined as the scanned volume of the patient.
Treatment planning
All treatment plans were made by the same treatment
planner. For every patient, four plans were created: WB
+ LNI to the whole axilla in prone and supine position,
and WB + LNI to the partial axilla in prone and supine
position. A coplanar multiple overlying partial arc
VMAT technique was used to avoid excessive low-dose
spread to the organs at risk [Fig. 2]. All plans were opti-
mized using GRATIS (Sherouse-on-Hudson Medical
Physics, High Falls, New York, United States) software
with in-house developed modifications. The final dose
calculation was performed using the collapsed cone con-
volution dose computation engine in Pinnacle3 9.8.
The dosimetric comparisons were made for 6 MV en-
ergy photon beams for an Elekta Synergy linear acceler-
ator (Elekta, Crawley, UK), equipped with an MLC with
a leaf-width of 5 mm.
Dose prescription and measured dose statistics
A median dose of 40.05 Gy in 15 fractions of 2.67 Gy
was prescribed to the PTV_WBI and PTV_LNI. The
objective was to cover 95% of the target volume with at
least 95% of the prescribed dose (i.e. 38 Gy), with no
more than 5% receiving 105% of the prescribed dose
Fig. 2 Illustration of the coplanar multiple overlying partial arc VMAT
technique. The yellow lines indicate beam apertures of the different
used beam angles, avoiding OAR such as the heart, lung and the
ipsilateral arm
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(i.e. 42 Gy). Dose heterogeneity was evaluated accord-
ing to the formula below, suggested in ICRU report 83
[28], where D2 and D98 are used as substitutes of the
maximal and minimal point dose in a delineated vol-
ume, because the latter two parameters are subject to
variations in dose-calculation parameters and therefore
less reliable.
H ¼ D2−D98
D50
Dose statistics are referred to as Dn (the minimal
dose delivered to n % of the volume) or Vn (the vol-
ume percentage receiving ≥ n Gy). We generated
dose-volume histograms (DVH) for all patients, show-
ing dosimetry for prone and supine treatment posi-
tions in either whole or partial axillary LNI [Figs. 3
and 4]. All patients required a boost to the tumor
bed, but because the location varied for each patient,
we did not include the boost dose in our analysis, so
as to preserve uniformity in our small patient group.
Hereby we were able to eliminate the risk of bias
when interpreting the dosimetry results and attribut-
ing changes caused by a boost dose to the way the
patient was positioned and vice versa.
Data analysis
Data was collected and analysed in R. We used non-
parametric testing for data analysis, because of the na-
ture of the data and inapplicability of the central limit
theorem in this group with limited sample size. Data on
PTV’s an OAR’s were compared and analysed per treat-
ment position and treatment plan (whole or partial
axillary LNI). After visual data inspection, we used a
one-sided Wilcoxon signed ranks test for related sam-
ples with a significance level of < 0.05.
Results
Dose statistics for targets and OAR’s are provided in
Tables 1 and 2. DVH’s are shown for both whole and
partial axillary LNI in Figs. 3 and 4. Reported results
apply to both axillary and partial axillary LNI unless
specified otherwise.
Target volumes
There was a small, but statistically significant difference
in CTV_WBI volume between both positions, i.e. 57 cc
lower in prone than in supine position. In contrast,
CTV_LNI volumes were significantly larger in prone
position. Planning objectives for PTV_WBI and
Fig. 3 Individual DVH’s for each patient in WB + LNI to the whole axilla
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PTV_LNI were reached with minimal differences in
D50, D95, D98, heterogeneity and hot spots between
prone and supine positions.
OAR’s
Significant differences were seen for ipsilateral lung
dose on all measured DVH parameters, favouring the
prone position. For the contralateral lung, a lower
mean dose and D2 were observed in prone position,
but differences in V5, V10, V20 or V30 were not signifi-
cant. The contralateral breast showed decreased
Dmean, D2 in prone as compared to supine position, as
well as decreased V5 values in total axillary LNI for the
prone position (P < 0.05). For the thyroid gland, Dmean,
D2, V5, V10, V20 and V30 values were significantly
lower in prone position (P < 0.05). Oesophageal Dmean
was slightly higher in supine as compared to prone
position, but there was also a volume difference, with
larger volumes in prone position. Partial axillary LNI
also showed a higher oesophageal D2 and V5 in supine
position. For the skin, there was a higher D2 in the
supine position in both LNI groups, as well as a higher
V105 and V107 for partial axillary LNI (P < 0.05). There
were no significant differences in DVH criteria for
doses to the heart or humeral head. Aside from the
oesophagus, there were no significant volume differ-
ences for OAR’s.
Discussion
Prone WBI has led to improved dose homogeneity
and reduced skin toxicity, while reducing the dose to
the lung and heart [8, 10–13, 22, 29–31]. Due to a
change in breast shape, path lengths are reduced and
skin folds disappear, resulting in lower acute and late
toxicity [22, 31].
Clinical data on prone WB + LNI is scarce. Shin et al.
[20] have reported on LNI in prone, with concomitant
WBI or chest wall irradiation. To our knowledge, this is
the only clinical data reporting on prone LNI. Treatment
in prone position showed significantly lower lung and
heart doses as compared to another patient group
treated to the same target regions in supine position.
They reported no grade >2 acute dermatitis and only 4%
of patients could not be treated in prone position. Long-
term toxicity was limited, but median follow up was just
under 3 years.
Gielda et al. [18] performed a study similar to our
own, comparing WB + LNI planning in supine and
Fig. 4 Individual DVH’s for each patient in WB + LNI to the partial axilla
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Table 1 Target volume dose parameters
Target Volumes Axilla prone Axilla supine Significance Partial axilla prone Partial axilla supine Significance
CTV_WBI
Volume (ml) 420 ± 165 477 ± 174 P < 0.05 420 ± 165 477 ± 174 P < 0.05
Dmean (Gy) 40.26 ± 0.09 40.34 ± 0.12 - 40.20 ± 0.10 40.27 ± 0.33 -
D02 (Gy) 42.12 ± 0.38 43.12 ± 0.80 - 42.16 ± 0.44 42.80 ± 0.35 P < 0.05
D05 (Gy) 41.74 ± 0.29 42.40 ± 0.49 - 41.72 ± 0.24 42.43 ± 0.41 P < 0.05
D50 (Gy) 40.21 ± 0.10 40.24 ± 0.16 - 40.03 ± 0.06 40.31 ± 0.41 -
D95 (Gy) 38.98 ± 0.16 38.63 ± 0.45 - 39.13 ± 0.24 38.00 ± 0.18 P < 0.05
D98 (Gy) 38.47 ± 0.24 38.01 ± 0.58 P < 0.05 38.72 ± 0.41 37.45 ± 0.23 P < 0.05
Heterogeneity 0.09 ± 0.01 0.13 ± 0.03 - 0.09 ± 0.02 0.13 ± 0.01 P < 0.05
PTV_WBI
Volume (ml) 483 ± 176 560 ± 204 P < 0.05 483 ± 176 560 ± 204 P < 0.05
Dmean 40.23 ± 0.09 40.19 ± 0.06 - 40.23 ± 0.07 40.15 ± 0.16 -
D02 42.26 ± 0.42 43.06 ± 0.75 - 42.34 ± 0.51 42.86 ± 0.19 -
D05 41.85 ± 0.32 42.34 ± 0.46 - 41.90 ± 0.30 42.46 ± 0.30 P < 0.05
D50 40.21 ± 0.10 40.18 ± 0.10 - 40.05 ± 0.02 40.19 ± 0.25 -
D95 38.76 ± 0.23 38.20 ± 0.50 P < 0.05 39.02 ± 0.31 37.68 ± 0.25 P < 0.05
D98 37.91 ± 0.48 36.54 ± 0.96 P < 0.05 38.45 ± 0.62 37.02 ± 0.30 P < 0.05
Heterogeneity 0.11 ± 0.02 0.16 ± 0.03 P < 0.05 0.10 ± 0.02 0.15 ± 0.01 P < 0.05
CTV_LNI
Volume (ml) 114 ± 31 89 ± 19 P < 0.05 51 ± 18 28 ± 3 P < 0.05
Dmean 40.30 ± 0.32 40.28 ± 0.13 - 40.12 ± 0.17 40.26 ± 0.15 -
D02 42.57 ± 0.55 42.94 ± 0.73 - 42.39 ± 0.34 42.32 ± 0.60 -
D05 42.09 ± 0.58 42.42 ± 0.55 - 41.99 ± 0.29 42.01 ± 0.19 -
D50 40.40 ± 0.27 40.23 ± 0.15 - 40.16 ± 0.13 40.33 ± 0.13 -
D95 38.42 ± 0.27 38.45 ± 0.28 - 37.99 ± 0.63 38.26 ± 0.36 -
D98 36.11 ± 2.07 37.47 ± 0.57 - 36.72 ± 1.22 37.54 ± 0.48 -
Heterogeneity 0.16 ± 0.05 0.14 ± 0.02 - 0.14 ± 0.03 0.12 ± 0.02 -
PTV_LNI
Volume (ml) 192 ± 51 152 ± 30 P < 0.05 82 ± 34 51 ± 6 -
Dmean 40.01 ± 0.35 40.07 ± 0.17 - 39.84 ± 0.31 40.04 ± 0.10 -
D02 42.55 ± 0.56 42.87 ± 0.62 - 42.31 ± 0.37 42.32 ± 0.31 -
D05 42.08 ± 0.56 42.27 ± 0.41 - 41.89 ± 0.32 41.96 ± 0.22 -
D50 40.27 ± 0.19 40.11 ± 0.15 P < 0.05 40.03 ± 0.10 40.15 ± 0.10 -
D95 37.02 ± 1.47 37.81 ± 0.32 - 36.86 ± 1.43 37.67 ± 0.22 -
D98 33.12 ± 4.25 36.11 ± 1.24 P < 0.05 34.40 ± 2.42 36.69 ± 0.39 -
Heterogeneity 0.23 ± 0.10 0.17 ± 0.03 - 0.20 ± 0.06 0.14 ± 0.01 -
PTV_LNI_opt
Volume (ml) 177 ± 50 134 ± 31 P < 0.05 75 ± 32 50 ± 6 -
Dmean 40.15 ± 0.24 40.11 ± 0.14 - 40.07 ± 0.13 40.06 ± 0.11 -
D02 42.53 ± 0.54 42.88 ± 0.65 - 42.33 ± 0.35 42.32 ± 0.31 -
D05 42.06 ± 0.55 42.32 ± 0.47 - 41.93 ± 0.30 41.97 ± 0.22 -
D50 40.29 ± 0.17 40.13 ± 0.13 P < 0.05 40.12 ± 0.09 40.16 ± 0.11 -
D95 38.18 ± 0.26 37.90 ± 0.31 - 38.10 ± 0.47 37.76 ± 0.19 -
D98 34.86 ± 2.90 36.32 ± 1.18 - 36.46 ± 0.73 36.78 ± 0.38 -
Heterogeneity 0.19 ± 0.07 0.16 ± 0.03 - 0.15 ± 0.02 0.14 ± 0.01 -
Data are presented as group average ± standard deviation
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Table 2 OAR dose volume parameters
Organs at Risk Axilla prone Axilla supine Significance Partial axilla prone Partial axilla supine Significance
Heart
Volume (ml) 631 ± 109 649 ± 141 - 631 ± 109 649 ± 141 -
Dmean (Gy) 2.38 ± 0.28 2.52 ± 0.59 - 2.24 ± 0.85 2.83 ± 0.61 -
D02 (Gy) 14.83 ± 1.64 14.02 ± 5.60 - 16.18 ± 10.22 18.75 ± 7.94 -
V5 (%) 7.10 ± 1.93 6.83 ± 3.56 - 6.60 ± 4.32 7.79 ± 2.32 -
V10 (%) 3.47 ± 0.92 3.51 ± 2.35 - 3.69 ± 2.86 4.12 ± 1.91 -
V20 (%) 1.04 ± 0.39 1.23 ± 1.20 - 1.60 ± 1.86 1.90 ± 1.45 -
V30 (%) 0.10 ± 0.18 0.06 ± 0.05 - 0.66 ± 1.10 0.64 ± 1.02 -
Ipsilateral lung
Volume (ml) 1240 ± 364 1158 ± 290 - 1240 ± 364 1158 ± 290 -
Dmean 5.52 ± 0.73 7.51 ± 1.03 P < 0.05 4.22 ± 0.53 6.82 ± 1.35 P < 0.05
D02 28.44 ± 1.16 34.28 ± 4.05 P < 0.05 29.71 ± 1.83 34.19 ± 1.93 P < 0.05
V5 28.85 ± 1.62 35.35 ± 2.11 P < 0.05 20.32 ± 3.09 31.81 ± 5.45 P < 0.05
V10 16.91 ± 2.94 23.80 ± 2.77 P < 0.05 11.82 ± 1.30 20.54 ± 5.39 P < 0.05
V20 7.13 ± 1.69 13.59 ± 3.22 P < 0.05 5.65 ± 1.03 11.47 ± 4.03 P < 0.05
V30 1.50 ± 0.47 5.49 ± 3.46 P < 0.05 1.94 ± 0.80 5.01 ± 2.54 P < 0.05
Contralateral lung
Volume (ml) 1536 ± 303 1458 ± 318 - 1538 ± 303 1458 ± 318 -
Dmean 0.35 ± 0.04 0.60 ± 0.09 P < 0.05 0.31 ± 0.05 0.84 ± 0.25 P < 0.05
D02 0.93 ± 0.06 1.93 ± 0.21 P < 0.05 0.90 ± 0.10 4.28 ± 2.95 P < 0.05
V5 0.00 ± 0.00 0.04 ± 0.07 - 0.00 ± 0.00 1.30 ± 1.67 -
V10 0.00 ± 0.00 0.01 ± 0.03 - 0.00 ± 0.00 0.45 ± 0.58 -
V20 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 0.01 ± 0.01 -
V30 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 0.00 ± 0.00 -
Contralateral breast
Volume (ml) 703 ± 235 665 ± 232 - 703 ± 235 665 ± 232 -
Dmean 0.33 ± 0.07 0.83 ± 0.30 P < 0.05 0.36 ± 0.10 1.01 ± 0.28 P < 0.05
D02 1.07 ± 0.16 2.54 ± 0.84 P < 0.05 1.30 ± 0.45 3.31 ± 1.70 P < 0.05
V5 0.02 ± 0.05 0.20 ± 0.23 P < 0.05 0.03 ± 0.04 0.86 ± 1.45 -
V10 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 0.00 ± 0.00 -
V20 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 0.00 ± 0.00 -
V30 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 0.00 ± 0.00 -
Thyroid
Volume (ml) 22 ± 14 19 ± 15 - 22 ± 14 19 ± 15 -
Dmean 5.38 ± 1.37 10.96 ± 4.11 P < 0.05 7.05 ± 1.64 12.21 ± 3.69 P < 0.05
D02 18.63 ± 7.53 36.04 ± 3.00 P < 0.05 33.91 ± 3.00 36.83 ± 1.88 P < 0.05
V5 28.29 ± 6.33 47.29 ± 19.64 P < 0.05 32.55 ± 8.44 50.32 ± 19.46 P < 0.05
V10 17.48 ± 4.82 37.49 ± 16.60 P < 0.05 23.55 ± 5.95 40.15 ± 16.76 P < 0.05
V20 7.64 ± 4.82 24.66 ± 11.42 P < 0.05 13.73 ± 4.58 28.07 ± 9.88 P < 0.05
V30 2.57 ± 2.13 12.57 ± 7.46 P < 0.05 5.47 ± 2.63 17.21 ± 7.72 P < 0.05
Oesophagus
Volume (ml) 35 ± 16 27 ± 12 P < 0.05 35 ± 16 27 ± 12 P < 0.05
Dmean 1.11 ± 0.09 1.74 ± 0.78 P < 0.05 1.12 ± 0.14 2.88 ± 1.75 P < 0.05
D02 3.36 ± 1.80 8.33 ± 8.96 - 4.49 ± 2.09 16.92 ± 14.49 P < 0.05
V5 1.00 ± 1.53 3.73 ± 5.14 - 1.70 ± 1.83 9.91 ± 8.21 P < 0.05
V10 0.06 ± 0.08 1.85 ± 4.03 - 0.26 ± 0.32 6.25 ± 8.12 -
V20 0.00 ± 0.00 0.87 ± 1.94 - 0.00 ± 0.00 3.42 ± 4.83 -
V30 0.00 ± 0.00 0.00 ± 0.00 - 0.00 ± 0.00 1.53 ± 2.59 -
Humeral Head
Volume (ml) 57 ± 15 63 ± 23 - 57 ± 15 63 ± 23 -
Dmean 9.75 ± 3.75 7.74 ± 2.94 - 9.85 ± 3.64 10.69 ± 3.33 -
D02 21.90 ± 1.49 25.08 ± 7.98 - 23.39 ± 2.10 27.22 ± 3.37 -
V5 69.76 ± 22.06 47.14 ± 23.45 - 64.46 ± 20.25 56.82 ± 13.37 -
V10 45.47 ± 31.68 23.87 ± 15.82 - 43.80 ± 25.85 45.89 ± 16.08 -
V20 4.05 ± 1.50 8.68 ± 7.57 - 9.25 ± 6.17 19.60 ± 13.52 -
V30 0.03 ± 0.06 1.98 ± 3.00 - 0.01 ± 0.03 1.37 ± 2.00 -
Skin
Volume (ml) 34353 ± 9812 22946 ± 4460 - 34353 ± 9812 22946 ± 4460 -
D02 38.40 ± 3.61 40.25 ± 0.15 P < 0.05 37.19 ± 5.16 39.95 ± 0.54 P < 0.05
V105 (%) 0.19 ± 0.14 0.30 ± 0.10 - 0.14 ± 0.10 0.38 ± 0.14 P < 0.05
V105 (ml) 58.48 ± 37.01 68.86 ± 25.29 - 44.28 ± 36.22 91.48 ± 45.69 P < 0.05
V107 (%) 0.06 ± 0.05 0.10 ± 0.05 - 0.03 ± 0.04 0.12 ± 0.09 P < 0.05
V107 (ml) 17.85 ± 13.43 21.85 ± 11.43 - 9.77 ± 12.94 29.68 ± 27.28 P < 0.05
Data are presented as group average ± standard deviation
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prone position on 10 patients treated with tangential
fields and one additional field to level IV. They observed
no significant difference in target coverage, but the
prone position resulted in lower dose to the ipsilateral
lung and contralateral breast.
Kainz et al. [19] performed a feasibility trial comparing
WB + LNI in prone position to previously reported su-
pine tomotherapy plans. In left sided breast cancer, they
showed lower heart and contralateral breast doses using
the prone position.
The novelty of this study lies in the use of the prone
crawl technique, with the ipsilateral arm alongside the
body, for prone WB + LNI. The crawl breast couch al-
lows beam access from underneath the patient without
traversing support materials. To our knowledge, this is
the first comparative study between prone and supine
WB + LNI with each patient serving as their own con-
trol, while also aiming to provide adequate target cover-
age to all regional nodes with the exception of the
internal mammary chain.
We were able to obtain treatment goals and con-
straints in all patients for either treatment position. The
unoptimized PTV_LNI in axillary LNI shows a slight
underdosage in prone when compared to supine position
(D98 of 33.12 Gy compared to 36.11 Gy for axillary LNI
and 34.40 Gy compared to 36.69 Gy for partial axillary
LNI), although planning goals were obtained. This differ-
ence was significant for the PTV_LNI but not for the
optimized PTV_LNI structure. We examined individual
prone plans to check for regions of systematic underdo-
sage, and compared these with the corresponding supine
plans. We found that both plans have underdosage in
the posterior inferomedial level IV region (where the in-
ternal mammary nodes start). This region is not easily
treated without incurring significant dose in the lungs
and thyroid, and therefore we allow a small underdosage
to this region, as long as the D95 constraint is met. The
difference between prone and supine plans, however,
was that this underdosed region lies more inward be-
cause of the prone-lateral positioning, resulting in a lar-
ger part of this region being underdosed. A second
difference is that using the delineation guidelines avail-
able, the PTV_LNI that was generated extended much
closer to the skin in prone than supine position in the
periclavicular region. This is why the PTV_LNI_opt does
not show significantly more underdosage.
There was a significant volume difference in the target
volumes between prone and supine position. For breast
tissue, the prone position results in lower absolute
volumes. It is possible that the crawl arm position does
not stretch the breast out longitudinally as much as with
elevated arms. Using a CT slice thickness of 5 mm, one
or two slices less can lead to a significant volume
difference.
The lymph node regions, however, have a larger abso-
lute volume in prone position. Results were significantly
different for whole axillary LNI, but not for partial axil-
lary LNI, probably because the largest volume differ-
ences were seen in the low axillary region (level I),
which is left out in partial axillary LNI. This might be
due to the anatomy changes to the structures that define
the lymph node regions in supine positioning, caused by
an anterior shift of the breast in prone position. The
breast “pulls” the lymph node regions anteriorly and
elongates them in the anteroposterior axis, while poster-
ior delineation margins, i.e. the subscapularis and latissi-
mus dorsi muscles, remain more or less in place. The
axillary levels III and IV are also more compressed in
the supine position due to arm elevation compared to
the crawl position with the arm alongside the body.
This study confirms the existing evidence of low-
ered ipsilateral lung doses in prone position, and adds
to the smaller body of evidence that this benefit
persists even when treating the regional lymph nodes
[8, 10–12, 18, 20–22, 30, 32]. Exposure of the lung to
radiotherapy increases the risk of second-primary lung
cancer (SPLC) development and death [33–35]. Our
data show a mean lung dose difference of 2.0 ±
1.0 Gy and 2.6 ± 0.9 Gy for axillary and periclavicular
LNI, respectively, in benefit of the prone position. A
dose response relationship with an increased RR for
SPLC of 0.20 per incremental Gy of mean lung dose
has been described by Inskip et al. [34]. Extrapolating
these data to our population, the prone position could
decrease the RR for ipsilateral lung cancer by 0.40 ±
0.20 and 0.52 ± 0.17 for axillary and periclavicular LNI
respectively, and would decrease SPLC incidence from
6.76 ± 0.92 to 4.97 ± 0.66 and from 6.14 ± 1.21 to 3.80
± 0.47 per year in 10,000 patients surviving 10 years
or more [34]. A case–control study by Grantzau et al.
showed that the rate of SPLC increased linearly with
8.5% per Gy in 5-year breast cancer treatment survi-
vors [36]. All DVH parameters for ipsilateral lung in
our study were significantly better in prone position.
We could estimate a decrease in absolute excess risk
of SPLC of up to about 50% in the highest lung dose
regions in our whole axillary LNI patient group
(291.38% ± 34.43% vs 241.74% ± 9.86%) and about 40%
in our partial axillary LNI group (290.62% ± 16.41% vs
252.54% ± 15.56%) by using the prone position.
The reported lung doses are well below the suggested
QUANTEC constraints [37] and the V5 constraint pro-
posed by Jo et al. to limit the risk of radiation pneu-
monitis [38]. We also note that the contralateral lung
receives less dose in prone than in supine position.
However, in this low-dose region, the contribution of
transmission and scatter dose is significant and treat-
ment planning systems cannot reliably calculate these
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doses. Therefore, the relevance of these reduced calcu-
lated doses is unclear.
The dose to the contralateral breast is also reduced in
prone position, likely because the crawl board allows
for more optimal positioning of the contralateral breast,
which is pulled away from the treatment fields and po-
sitioned in a shallow recess etched into the wedge. This
further decreases the chance of the contralateral breast
slipping off the wedge towards the treatment field. This
decreased the D2 by about 50%, which could reduce
the excess risk for contralateral breast cancer (CBC) at
longer follow-up intervals [39–41].
The most pronounced dosimetrical difference be-
tween prone and supine treatment plans was observed
for thyroid dose. In paediatric patients, a dose-response
relationship has been described for secondary thyroid
cancer [42], but these results have not been reproduced
in breast cancer patients, where thyroid doses are gen-
erally lower. One Taiwanese study described an overall
increased risk for thyroid cancer in breast cancer pa-
tients, regardless of irradiation [43]. They did not see
an excess risk of thyroid cancer after radiotherapy for
breast cancer. A meta-analysis by Grantzau and Over-
gaard failed to show an association between radio-
therapy and secondary thyroid cancer in breast cancer
patients [44]. However, a link has been demonstrated
between radiation therapy and hypothyroidism. A
meta-analysis by Vogelius et al. synthesizes multiple
dose-responserelationships into one compounded model,
indicating a 50% chance of developing hypothyroidism
when the thyroid dose exceeded 45.15 Gy (95% CI
27.87 Gy – 62.43 Gy). The authors describe the dose-
responserelationship as moderately steep, which indicates
that incidence of hypothyroidism could be decreased by
even a relatively small thyroid dose reduction [45]. Com-
paring the crawl with supine position, there was an
important decrease in the thyroid dose using the crawl de-
vice for the low doses. This difference was even more pro-
nounced for the high dose regions. The mean thyroid
dose was halved, potentially indicating a substantial
decrease in risk for radiation induced hypothyroidism.
For oesophageal doses, we noticed a decreased
mean dose in prone position for axillary and partial
axillary LNI, as well as lowered D2 and V5 in
prone position for partial axillary LNI. As we also
saw a significant increase in oesophageal volume in
prone position, care needs to be taken to interpret
differences between the two treatment positions. This
volume difference is not explained by a difference in
delineation, because the same oesophageal contouring
method was used in prone and supine position. Thus,
the volume change must be explained by the posture
change in prone position. To our knowledge, this
finding has not been reported elsewhere. Grantzau &
Overgaard reported an association between radiother-
apy and second oesophageal cancer, starting from
5 years post-radiation, with the RR increasing with
time [44]. Decreasing the oesophageal dose may re-
duce secondary oesophageal cancer risk.
These dose reductions to the thyroid and oesophagus
could be inherent to the prone position, but we
hypothesize that these changes are more likely explained
by to the different arm position. In the crawl position,
the lymph node regions are moved away from the neck,
thereby reducing doses to these organs.
One point of comment could be that the position of the
arm next to the body might increase the dose to the arm
and humeral head, because they are positioned closer to
the affected breast. Irradiation of muscles and joints in
this region could decrease mobility. Care also needs to be
taken that the arm is not positioned in contact with the
target regions, because this reduces possible beam direc-
tions for LNI and WBI. Moreover, it could eliminate
build-up regions, increasing skin toxicity. Our study shows
no significant difference in dose to the humeral head.
Prone radiotherapy for the breast improves cardiac
dose in most patients, especially in large breasted
patients [10–12]. We observed a slightly lower heart
dose in prone position, but failed to show a significant
difference between the two treatment positions. How-
ever, in this study, patients were small breasted, all with
breast volumes < 1000 ml in prone position. Breast vol-
ume exceeded 750 ml in only 2 patients, and mean
breast volume was 658 ml (range 292–892 ml, standard
deviation = 237 ml). The UK HeartSpare study showed
that breath-hold techniques are more efficient in lo-
wering heart dose than prone position [16, 17]. How-
ever, it has been demonstrated that prone breath-hold
for WBI without LNI is feasible and at least as efficient
as supine breath-hold. Moreover, it is easy to imple-
ment since the irradiated breast does not move as
much as in supine position [14, 15]. The feasibility of
breath-hold for WB + LNI in prone crawl position
merits further investigation.
Data on prone WB + LNI are sparse, and comparisons
are not straightforward. Shin et al. [20] report lower
doses to the heart and ipsilateral lung, but over half of
their patients had right sided breast cancer. They also
limited LNI to level III-IV. Kainz et al. [19] report on
helical tomotherapy for WB + LNI, with heart, contra-
lateral breast, ipsilateral lung, thyroid and oesophageal
doses that are substantially higher than in our study.
However, in addition to levels I-IV, they included the
internal mammary nodes for LNI, which makes direct
comparison unfair. Lastly, Gielda et al. [18] had a similar
trial setup, with comparable ipsilateral lung dose, but we
report lower heart and contralateral breast doses, with
improved nodal coverage in our trial.
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One of the weaknesses of this study is the small pa-
tient group. Undertaking a similar study on a larger
patient group could be viewed as unethical, because
maintaining an intra-patient comparison requires more
patients to undergo a second CT scan without clinical
benefit, and increased radiation exposure. We preferred
to study a small patient group, and proceed to a clinical
trial, as results were favourable in this group. Another
weakness is the use of non-parametric testing of the
dosimetric values because of the limited number of ob-
servations and the data not always being distributed nor-
mally. To reduce variability between patients in this
small group, we excluded boost doses to the tumor bed
from our analysis. It stands to reason that prone posi-
tioning will yield lower OAR doses than supine posi-
tioning, because this data already exists for WBI.
However, as the boost dose was not analysed in our
study, we can only make the assumption that OAR doses
will be lower in prone crawl positioning. The non-
parametric method uses value ranks rather than absolute
values and the significance level could be less clear, as
non-parametric tests are more conservative, meaning
that achieving significance in these tests is harder. We
chose to perform a one-sided test, because it is mathemat-
ically impossible to achieve significance using a 2-sided
test with confidence level of 0.05 in a paired sample
Wilcoxon test with five test subjects. Overall, individual
patient results were in favour of prone positioning.
The exclusion of the internal mammary nodes from
the nodal target volumes is debatable. Recent evidence
shows improved disease outcomes, but these studies
have some flaws which make generalisation difficult.
Poortmans et al. [2] randomized between WBI or thor-
acic wall irradiation without LNI or with LNI to both
the internal mammary nodes and medial supraclavicular
nodes. It is unclear if the benefits in this trial relate to
LNI to the internal mammary nodes specifically. Fur-
thermore, breast cancer mortality was significantly re-
duced in the LNI group, but overall mortality reductions
were not statistically significant (although P was only
0.06), indicating a possible treatment related mortality.
Whelan et al. [3] also randomized between WBI with
LNI to the internal mammary, supraclavicular and axil-
lary nodes or WBI without LNI. They saw improved
disease-free survival but no overall survival benefit for
LNI. Furthermore, side-effects such as acute pneu-
monitis and lymphedema were increased in the LNI
group. A trial by Thorsen et al. [46] treated right sided
breast cancer patients with LNI to the internal mam-
mary nodes and left sided breast cancer patients without
LNI to the internal mammary nodes. Survival was im-
proved in patients treated with internal mammary node
irradiation, but results cannot be extrapolated to left
sided breast cancer patients because of the increased
toxicity risk due to radiation exposure of the heart in left
sided breast cancer patients. Because of the unclear
overall survival benefit and the higher treatment related
toxicity and mortality risk, elective internal mammary
node irradiation is not done routinely at our institution.
We are confident, however, that improvements in radi-
ation technique and patient positioning can decrease the
dose to OARs and possibly decrease treatment related
toxicities. The crawl couch allows beam incidences to
treat the internal mammary nodes differently than in su-
pine position. Given the recent evidence hinting at a bene-
ficial effect of LNI to the internal mammary nodes, we are
currently conducting a study where the internal mammary
nodes are included in the nodal treatment volumes.
A last weakness is the absence of contouring guide-
lines for prone WB + LNI, which is why we extrapolated
from existing guidelines. Our results hint at anatomic
differences between the nodal target regions, which
might have led to higher OAR doses. Developing an evi-
dence based guideline for prone WB + LNI could de-
crease these doses, but this evidence will first have to be
generated through further research.
Conclusions
This pilot study demonstrates that prone crawl position
for WB + LNI allows for good coverage of the nodal tar-
gets with better sparing of ipsilateral lung, thyroid,
contralateral breast, contralateral lung and oesophagus
compared to the supine position.
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